公开(公告)号：US20100129788A1

公开(公告)日：2010-05-27

申请号：US12522623

申请日：2008-01-24

申请人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

发明人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

IPC分类号： C12Q1/70

CPC分类号： C12Q1/707 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

摘要： A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably M×A, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.

摘要翻译： 描述了用于评估在I型干扰素治疗的个体中预防I型（IFN）的生物学作用的因子的体内存在的方法。 在用I型干扰素治疗的个体中评估针对I型干扰素（IFN）的抗体的体内存在。 该方法包括将体外血液样品与适量的I型干扰素孵育合适的时间，并测定血液样品中IFN活性，优选M×A的生物学标志物的mRNA水平。 该治疗可涉及使用I型干扰素治疗多发性硬化症，HCV或HBV。

公开(公告)号：US08426170B2

公开(公告)日：2013-04-23

申请号：US12522623

申请日：2008-01-24

申请人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

发明人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

IPC分类号： C12P19/34

CPC分类号： C12Q1/707 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

摘要： A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably MxA, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.

摘要翻译： 描述了用于评估在I型干扰素治疗的个体中预防I型（IFN）的生物学作用的因子的体内存在的方法。 在用I型干扰素治疗的个体中评估针对I型干扰素（IFN）的抗体的体内存在。 该方法包括将体外血液样品与合适量的I型干扰素孵育合适的时间，并测定血液样品中IFN活性生物学标志物，优选MxA的mRNA水平。 该治疗可涉及使用I型干扰素治疗多发性硬化症，HCV或HBV。

公开(公告)号：US20120190031A1

公开(公告)日：2012-07-26

申请号：US13203531

申请日：2010-03-25

申请人： Patrick Stordeur ,  Françoise Villée ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

发明人： Patrick Stordeur ,  Françoise Villée ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

IPC分类号： C12Q1/68

CPC分类号： G01N33/6869 ,  G01N33/6896 ,  G01N2333/545 ,  G01N2800/285

摘要： The invention provides an improved method for monitoring the course of the MS disease and to predict, diagnose or prognosticate whether a subject is in an active or non-active period of MS. The method is based on determining the ratio of the expression levels of two cytokines, measured before and after stimulation of the subject by an immunomodulator.

摘要翻译： 本发明提供了一种用于监测MS疾病进程并预测，诊断或预测受试者是否处于MS的活动期或非活动期的改进方法。 该方法基于通过免疫调节剂测定受试者刺激之前和之后测量的两种细胞因子的表达水平的比例。